Summary
DHRC Chart
Why Danaher (DHR) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Danaher: High Capex And Low Debt Despite Trump Legislation
The company has achieved returns on equity above 7.8% since 2019. Additionally, it reduced its liabilities-to-assets ratio to 35.72% this quarter, indicating a low risk of bankruptcy. Danaher expects an excellent growth outlook in the upcoming years, due to the significant investment that the biopharma industry has dedicated to developing new medical therapies. Between 2017 and 2024, Danaher invested 25.81% of its revenues to expand its operations, which has contributed to the growth rate of its revenues.
Danaher Schedules Second Quarter 2025 Earnings Conference Call
WASHINGTON , June 17, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the second quarter 2025 on Tuesday, July 22, 2025 beginning at 8:00 a.m. ET and lasting approximately one hour.
Danaher Corporation Dividends
 DHR In 4 days Announced | Quarterly | $0.32 Per Share |
| DHR 2 months ago Paid | Quarterly | $0.32 Per Share |
| DHR 5 months ago Paid | Quarterly | $0.27 Per Share |
| DHR 8 months ago Paid | Quarterly | $0.27 Per Share |
| DHR 11 months ago Paid | Quarterly | $0.27 Per Share |
Danaher Corporation Earnings
| 21 Jul 2025 (In 4 weeks) Date | | - Cons. EPS | - EPS |
| 21 Apr 2025 Date | | - Cons. EPS | - EPS |
| 29 Jan 2025 Date | | 2.14 Cons. EPS | 2.14 EPS |
| 28 Jan 2025 Date | | 2.14 Cons. EPS | - EPS |
| 22 Oct 2024 Date | | 1.57 Cons. EPS | 1.71 EPS |
| DHR In 4 days Announced | Quarterly | $0.32 Per Share |
| DHR 2 months ago Paid | Quarterly | $0.32 Per Share |
| DHR 5 months ago Paid | Quarterly | $0.27 Per Share |
| DHR 8 months ago Paid | Quarterly | $0.27 Per Share |
| DHR 11 months ago Paid | Quarterly | $0.27 Per Share |
| 21 Jul 2025 (In 4 weeks) Date | | - Cons. EPS | - EPS |
| 21 Apr 2025 Date | | - Cons. EPS | - EPS |
| 29 Jan 2025 Date | | 2.14 Cons. EPS | 2.14 EPS |
| 28 Jan 2025 Date | | 2.14 Cons. EPS | - EPS |
| 22 Oct 2024 Date | | 1.57 Cons. EPS | 1.71 EPS |
Danaher Corporation (DHRC) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Danaher Corporation ever had a stock split?
Danaher Corporation Profile
| Medical - Diagnostics & Research Industry | Healthcare Sector | Mr. Rainer M. Blair CEO | XWBO Exchange | US2358511028 ISIN |
| US Country | 61,000 Employees | 28 Mar 2025 Last Dividend | 2 Oct 2023 Last Split | 5 Jan 1979 IPO Date |
Overview
Danaher Corporation is a global powerhouse in the design, manufacturing, and marketing of a vast array of professional, medical, industrial, and commercial products and services. With its inception in 1969 and a significant rebranding in 1984, where it transitioned from Diversified Mortgage Investors, Inc. to Danaher Corporation, the company has established a formidable presence in various sectors. Headquartered in Washington, D.C., Danaher stands out through its commitment to innovation, excellence, and enhancing the quality of life worldwide.
Products and Services
- Biotechnology: Danaher's biotechnology segment is a provider of bioprocess technologies, consumables, and services enhancing the development and manufacture of therapeutics. This includes cell line and cell culture media development, chromatography resins, filtration technologies, aseptic fill-finish solutions, single-use hardware, and comprehensive services aimed at setting up full manufacturing suites.
- Life Sciences: This segment delivers a wide range of products including mass spectrometers, flow cytometry, genomics solutions, lab automation instruments, centrifugation, liquid handling automation instruments, antibodies and reagents, particle counting and characterization tools, microscopes, and protein consumables. Among the notable brands under the Life Sciences segment are ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX, each providing specialized products for genomic medicines and industrial filtration.
- Diagnostics: Danaher’s diagnostics sector offers a comprehensive range of chemistry, immunoassay, microbiology, automation systems, molecular diagnostics, acute care, and pathology diagnostics products. Aimed at hospitals, physicians' offices, reference laboratories, and other critical care settings, this segment ensures the delivery of clinical instruments, reagents, consumables, software, and dedicated services to support critical diagnostics.
Contact Information
